August 1, 2004

B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximab

Key Points

Key points are not available for this paper at this time.

Abstract

Rituximab therapy appears to be safe for the treatment of SLE and holds significant therapeutic promise, at least for the majority of patients experiencing profound B cell depletion. Based on these results, controlled trials of rituximab appear to be warranted.

Demander à l'IA

Bookmark

Cite This Study

Looney et al. (Sun,) studied this question.

synapsesocial.com/papers/69d7002299397875bbaa80a1 https://doi.org/https://doi.org/10.1002/art.20430

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.1983 · 69 citations
2FcγRIIa Is Expressed on Natural IFN-α-Producing Cells (Plasmacytoid Dendritic Cells) and Is Required for the IFN-α Production Induced by Apoptotic Cells Combined with Lupus IgG2003 · 378 citations
3Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells.1987 · 106 citations
4Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial1999 · 2,357 citations
5The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited2004 · 1,999 citations

Demander à l'IA

Bookmark